Treprostinil Platform Expansion Into Lung Diseases Will Drive Powerful Long Term Upside

AnalystHighTarget

Analyst High Target compiles bullish analysts opinions to create narratives which represent one standard deviation above the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls

Published

08 Dec 25

Updated

10 Jul 26

Views

Not Invested

Shared on 10 Jul 26

Fair value Increased 54%

LQDA: Legal Outcomes Around Key Patent Will Drive Future Upside

Liquidia’s outlook shifts as analysts raise their view of the company, mainly on stronger expectations for YUTREPIA and a more hopeful read of recent court rulings. The big swing factor now is what happens next in the key patent fight, with some watching from the sidelines until there’s more clarity.

9 views

Fair Value vs Share Price

US$102.99

vs US$84.4218.0% undervalued

80.3%

Revenue growth

51.4%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Liquidia

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

High growth potential with adequate balance sheet.

Market capUS$7.7b

PB69.1x

Estimated Growth25.3%

Dividend YieldN/A

Full analysis

CEO & management

Roger Jeffs

CEO

3.0yrs

CEO Tenure

A biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.